Back to top
more

Theravance Biopharma (TBPH)

(Delayed Data from NSDQ)

$11.92 USD

11.92
589,080

+0.52 (4.56%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $12.34 +0.42 (3.52%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (85 out of 245)

Industry: Medical - Drugs

Zacks News

Zacks Equity Research

Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline

Theravance (TBPH) reports narrower-than-expected loss in the second quarter of 2022. Revenues improve year over year due to Viatris collaboration.

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of 33.33% and 36.75%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Jazz (JAZZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Theravance Biopharma (TBPH) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

Theravance Bio (TBPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests

Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.

Zacks Equity Research

Is the Options Market Predicting a Spike in Theravance (TBPH) Stock?

Investors need to pay close attention to Theravance (TBPH) stock based on the movements in the options market lately.

Zacks Equity Research

Theravance's (TBPH) Q1 Earnings and Sales Miss Estimates

Theravance (TBPH) reports wider-than-expected loss for the first quarter of 2022. Revenues decline year over year.

Zacks Equity Research

Theravance Biopharma (TBPH) Reports Q1 Loss, Lags Revenue Estimates

Theravance Bio (TBPH) delivered earnings and revenue surprises of -100% and 20.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Theravance Biopharma (TBPH) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

Theravance Bio (TBPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Theravance's (TBPH) Hypotension Study Misses Primary Goal

Theravance's (TBPH) phase III study on ampreloxetine for treating symptomatic nOH fails to meet its goal. The study benefitted patients with a rare neurodegenerative disorder.

    Zacks Equity Research

    Why Is Theravance Bio (TBPH) Up 0.4% Since Last Earnings Report?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

    Zacks Equity Research

    Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates

    Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

    Zacks Equity Research

    Theravance Biopharma (TBPH) Reports Q4 Loss, Lags Revenue Estimates

    Theravance Bio (TBPH) delivered earnings and revenue surprises of -43.33% and 4.14%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Equity Research

    Drug/Biotech Stocks' Q4 Earnings on Feb 23: BMRN, BHC & More

    Let us take a look at five drug/biotech companies, namely, BMRN, CLVS, TBPH, BHC and GBT, which are due to release their quarterly results on Feb 23.

    Zacks Equity Research

    Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

    Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

    Zacks Equity Research

    Wall Street Analysts Think Theravance Bio (TBPH) Could Surge 27%: Read This Before Placing a Bet

    The mean of analysts' price targets for Theravance Bio (TBPH) points to a 26.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

    Zacks Equity Research

    Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

    Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

    Zacks Equity Research

    CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

    CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

    Zacks Equity Research

    Zoetis' (ZTS) Q4 Earnings and Revenues Surpass Estimates

    Zoetis' (ZTS) earnings and revenues beat estimates for the fourth quarter of 2021.

    Zacks Equity Research

    Zacks.com featured highlights include Theravance Biopharma, PattersonUTI Energy and Select Energy Services

    Theravance Biopharma, PattersonUTI Energy and Select Energy Services are included in this blog.

    Tirthankar Chakraborty headshot

    3 Best Stocks to Buy Right Away for Earnings Acceleration

    Invest in Theravance Biopharma (TBPH), PattersonUTI Energy (PTEN) & Select Energy Services (WTTR) at the moment for superb earnings acceleration.

    Zacks Equity Research

    Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse

    Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.

    Zacks Equity Research

    Lannett (LCI) Reports Q2 Loss, Misses Revenue Estimates

    Lannett (LCI) delivered earnings and revenue surprises of -21.88% and 14.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

    Zacks Equity Research

    Implied Volatility Surging for Theravance Biopharma (TBPH) Stock Options

    Investors need to pay close attention to Theravance Biopharma (TBPH) stock based on the movements in the options market lately.

    Zacks Equity Research

    Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound?

    Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.